Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of caffeine on intestinal absorption of ergotamine in man.

Literature DB >> 4851611

Effect of caffeine on intestinal absorption of ergotamine in man.

R Schmidt, A Fanchamps.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 1974 PMID： 4851611 DOI： 10.1007/bf00560383

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

12 in total

1. Further observations in craniovascular studies.

Authors: P BRAZIL; A P FRIEDMAN
Journal: Neurology Date: 1957-01 Impact factor: 9.910

2. [Recent work on pathogenesis and treatment of headache].

Authors: E PICHLER
Journal: Wien Med Wochenschr Date: 1956-12-15

3. Craniovascular studies in headache; a report and analysis of pulse volume tracings.

Authors: P BRAZIL; A P FRIEDMAN
Journal: Neurology Date: 1956-02 Impact factor: 9.910

4. Treatment of the migraine attack.

Authors: A P FRIEDMAN; C BRENNER
Journal: Am Pract Dig Treat Date: 1948-03

5. The treatment of headache; with particular reference to the use of cafergone for the relief of attacks.

Authors: F K HANSEL
Journal: Ann Allergy Date: 1949 Mar-Apr

6. Recent advances in treatment of migraine.

Authors: A P FRIEDMAN; T J C VON STORCH
Journal: J Am Med Assoc Date: 1951-04-28

7. Observations on the symptomatic treatment of chronic vascular headache with cafergone (ergotamine tartrate and caffeine).

Authors: S G COHEN; L H CRIEP
Journal: N Engl J Med Date: 1949-12-08 Impact factor: 91.245

8. Complexes of ergot alkaloids and derivatives. I. The interaction of caffeine with ergotamine tartrate in aqueous solution.

Authors: M A Zoglio; H V Maulding; J J Windheuser
Journal: J Pharm Sci Date: 1969-02 Impact factor: 3.534

9. TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives.

Authors: N A Bercel
Journal: Calif Med Date: 1950-04

10. Controlled clinical trial of ergotamine tartrate.

Authors: W E Waters
Journal: Br Med J Date: 1970-05-09

16 in total

1. Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach.

Authors: Megan Miller; Avinash B Kumar; Charles R Callison
Journal: Neuroradiology Date: 2011-04-06 Impact factor: 2.804

2. Methylxanthines and intestinal drug absorption.

Authors: E Beubler; F Lembeck
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1976 Impact factor: 3.000

3. Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay.

Authors: T T Kleimola
Journal: Br J Clin Pharmacol Date: 1978-09 Impact factor: 4.335

4. Absorption kinetics of dihydroergotoxine following oral administration to man.

Authors: B G Woodcock; N Rietbrock; W Loh; W D Habedank
Journal: Br J Clin Pharmacol Date: 1985-12 Impact factor: 4.335

5. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.

Authors: K W Evans; J A Boan; J L Evans; A Shuaib
Journal: Pharmacoeconomics Date: 1997-11 Impact factor: 4.981

Review 6. Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors: V L Perrin
Journal: Clin Pharmacokinet Date: 1985 Jul-Aug Impact factor: 6.447

Review 7. Pharmacological rationale for the clinical use of caffeine.

Authors: J Sawynok
Journal: Drugs Date: 1995-01 Impact factor: 9.546

Review 8. Migraine and drug absorption.

Authors: G N Volans
Journal: Clin Pharmacokinet Date: 1978 Jul-Aug Impact factor: 6.447

9. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors: J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal: Br J Clin Pharmacol Date: 1983-12 Impact factor: 4.335

10. Ergotamine absorption and toxicity.

Authors: D A Orton; R J Richardson
Journal: Postgrad Med J Date: 1982-01 Impact factor: 2.401